ZERO100
25.5.2023 13:31:29 CEST | Business Wire | Press release
Zero100 has today announced that Andrea Albright, EVP Sourcing, Walmart has been appointed to the Zero100 Advisory Board.
“I’m honored to join Zero100’s Advisory Board and look forward to collaborating with a community of leaders who are working across the value chain to build resiliency and accelerate decarbonization,” said Andrea Albright, EVP Sourcing, Walmart. “We have a unique window on the world due to our global footprint, and I’m excited to share insights from Walmart and tap into the wealth of knowledge that Board members will bring to our shared journey, as we work to reach zero emissions.”
Olly Sloboda, Chief Executive Officer at Zero100 adds: “We are privileged to welcome Andrea to the Board. Andrea’s wealth of experience across multiple global business leadership roles at Walmart, including her current role leading arguably the most influential global sourcing organization, made her an obvious choice to help accelerate the Zero100 Board’s collective mission. And Walmart’s journey from a small discount retailer to the world’s largest, is a story of bold innovation and evolution; two critical capabilities our Zero100 community must embrace as we harness new technologies to radically reinvent supply chains on behalf of consumers around the world.”
About Walmart
Walmart Inc. (NYSE: WMT) helps people around the world save money and live better - anytime and anywhere - in retail stores, online, and through their mobile devices. Each week, approximately 240 million customers and members visit more than 10,500 stores and numerous eCommerce websites in 20 countries. With fiscal year 2023 revenue of $611 billion, Walmart employs approximately 2.1 million associates worldwide. Walmart continues to be a leader in sustainability, corporate philanthropy, and employment opportunity. Additional information about Walmart can be found by visiting corporate.walmart.com, on Facebook at facebook.com/walmart, on Twitter at twitter.com/walmart, and on LinkedIn at linkedin.com/company/walmart. Recognized as the Most Trusted Brand for Digital Payments as per the Brand Trust Report 2022 by Trust Research Advisory (TRA).
About Zero100
The world’s most influential and forward-thinking Chief Operations and Supply Chain Officers partner with Zero100, a membership-based research and intelligence organization, to accelerate progress on Digital Supply Chain Transformation. Members share a common purpose – to harness new technology to re-invent the production, distribution and consumption of physical goods around the world.
Zero100’s approach combines unique IP-led research and data, intimate executive-level events, personalized guidance and access to an extensive community of influential thinkers and voices from within, and beyond, supply chain.
The company is headquartered in London, UK, with offices in New York, USA.
Zero100 Advisory Board Members
To find out more, including a full list of our Advisory Board Members, visit https://zero100.com/about-us/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523006025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 09:00:00 CEST | Press release
Kvvit to lead local development, regulatory activities and commercialization of INBRIJA® in mainland China, Hong Kong and Macao Under the agreement, Merz Therapeutics will receive upfront, development and commercial milestone payments, and tiered supply and royalty arrangements, with no manufacturing rights granted to Kvvit Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercializat
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 08:49:00 CEST | Press release
IQM Radiance R1 is the first on-premises quantum computer for the PUT. The university aims to use the system to spearhead quantum education and research while boosting STEM in the country. This is the second operational quantum computer deployed in Poland by IQM. The university recognizes the significant long-term potential of integrating quantum computing, artificial intelligence, and high-performance computing (HPC), and intends to play a key role in shaping this transformation in Europe. Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weyde
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 08:30:00 CEST | Press release
BearingPoint is expanding its AI portfolio with a fully owned, sovereign on-premise and edge infrastructure designed specifically for generative and agentic AI workloads in highly regulated industries and public administrations in Europe. Building on decades of experience operating its own sovereign cloud, the firm now offers clients both dedicated hardware and token-based access to large language models – fully GDPR-compliant, ISO-certified and, on request, NIS2- and DORA-ready BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical sc
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 08:00:00 CEST | Press release
Study Topline results will be released around the end of Q2 2026 BIA 28-6156 is being developed as a potential first-in-class disease-modifying therapy in GBA-PD Bial was present at the GBA1 conference and is currently attending the World Parkinson Congress Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Pho
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 07:00:00 CEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom